Preventing SARS-CoV-2 In-Hospital Infections in Cardiovascular Patients and Medical Staff: An Observational Study From the German Heart Center Berlin.

Autor:	Schöppenthau D; Department of Internal Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.; DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany., Weiß KJ; Department of Internal Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.; DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany., Estepa-Martinez M; Department of Internal Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany., Hommel M; Deutsches Herzzentrum Berlin, Department of Cardioanaestesiology and Intensive Care, Berlin, Germany., Miera O; Department of Congenital Heart Disease - Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany., Schoenrath F; DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.; Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany., Hübler S; Deutsches Herzzentrum Berlin, Berlin, Germany., Obermeier M; Deutsches Herzzentrum Berlin, Berlin, Germany.; Laboratory MVZ MIB AG (Medizinisches Versorgungszentrum - Medizinisches Infektiologiezentrum Berlin AG), Berlin, Germany., Pieske B; Department of Internal Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.; DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.; Department of Cardiology, Campus-Virchow, Charité Universitätsmedizin Berlin, Berlin, Germany., Stawowy P; Department of Internal Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.; DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2021 Feb 03; Vol. 7, pp. 616648. Date of Electronic Publication: 2021 Feb 03 (Print Publication: 2020).
DOI:	10.3389/fmed.2020.616648
Abstrakt:	Objective: COVID-19 is a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Preventing in-hospital infections is crucial to protect patients and hospital staff. Methods: At the very beginning of the COVID-19 pandemic, the German Heart Center initiated obligatory wearing of surgical face masks for patients and employees, SARS-CoV-2 screening for all patients, and symptom-based testing for employees. In addition, access restriction, closure of outpatient departments, and postponing non-urgent procedures were implemented with community-initiated regulations. Results: During the observation period (03/16/2020-04/27/2020), 1,128 SARS-CoV-2 tests were performed in 983 persons (1.1 tests/person; 589 in patients and 394 in hospital employees). Up to 60% of the clinical workforce was tested based on symptoms and risk (62.5% symptoms, 19.3% direct or indirect contact to known COVID-19, 4.5% returnee from risk area, 13.7% without specific reason). Patient testing for SARS-CoV-2 was obligatory (100% tested). The overall prevalence of positive tests during the observation period was 0.4% ( n = 5 out of 1,128 tests performed). The incidence of new infections with SARS-CoV-2 was 0.5% ( n = 5 out of 983 individuals; three healthcare workers, two patients). No nosocominal infections occurred, despite a mean number of 14.8 in-hospital contacts. Conclusion: Comprehensive SARS-CoV-2 testing and surgical face masks for patients and hospital staff, in addition to others measures, are key factors for the early detection of COVID-19 and to prevent spreading in the vulnerable hospital population. Competing Interests: DS received travel grants from St. Jude Medical, Bristol-Myers-Squibb and Biosense Webster, a research grant from Biosense Webster and took part in the Boston scientific EP fellowship program. FS reports non-financial support from Medtronic, grants from Novartis, grants from Abbott, personal fees from Cardiorentis, outside the submitted work. BP reports having received consultancy and lecture honoraria from Bayer, Daiichi Sankyo, MSD, Novartis, Sanofi-Aventis, Stealth Peptides and Vifor Pharma; and editor honoraria from the Journal of the American College of Cardiology. PS has received consultancy and lecture honoraria from Amgen, Novartis, Sanofi-Aventis, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, BerlinChemie, B. Braun, Medtronic, AstraZeneca and editor honoraria from Springer Nature. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Schöppenthau, Weiß, Estepa-Martinez, Hommel, Miera, Schoenrath, Hübler, Obermeier, Pieske and Stawowy.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu